Participation of 5-lipoxygenase-derived LTB4 in 4-hydroxynonenal-enhanced MMP-2 production in vascular smooth muscle cells

Atherosclerosis

Volumn 208, Issue 1, 2010, Pages 56-61

  Seo, Kyo W ^a,b   Lee, Seung J ^a,b   Kim, Chae E ^a,b   Yun, Mi R ^a,b   Park, Hye M ^a,b   Yun, Jung W ^a,b   Bae, Sun S ^a,b   Kim, Chi D ^a,b  

^a Pusan National University   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

4 Hydroxynonenal; 5 Lipoxygenase; Leukotriene B4; MMP 2; VSMC

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2,6 DIHYDROXYHEXYL) 6 (3 HYDROXY 1,5 UNDECADIENYL)PYRIDINE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 HYDROXYNONENAL; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; ARACHIDONATE 5 LIPOXYGENASE; GELATINASE A; LEUKOTRIENE B4; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; VERLUKAST;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME SYNTHESIS; IMMUNOBLOTTING; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ZYMOGRAPHY;

ALDEHYDES; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CELLS, CULTURED; LEUKOTRIENE B4; MATRIX METALLOPROTEINASE 2; MICE; MUSCLE, SMOOTH, VASCULAR;

EID: 73449139739     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.06.012     Document Type: Article

References (41)

1. Bonomini F., Tengattini S., Fabiano A., Bianchi R., and Rezzani R. Atherosclerosis and oxidative stress. Histol Histopathol 23 (2008) 381-390
2. Kumagai T., Ikezoe T., Gui D., et al. RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. Clin Cancer Res 10 (2004) 1508-1520
3. Leonarduzzi G., Chiarpotto E., Biasi F., and Poli G. 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Mol Nutr Food Res 49 (2005) 1044-1049
4. Madamanchi N.R., Hakim Z.S., and Runge M.S. Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. J Thromb Haemost 3 (2005) 254-267
5. Lee J.Y., Jung G.Y., Heo H.J., et al. 4-Hydroxynonenal induces vascular smooth muscle cell apoptosis through mitochondrial generation of reactive oxygen species. Toxicol Lett 166 (2006) 212-221
6. Sampey B.P., Carbone D.L., Doorn J.A., Drechsel D.A., and Petersen D.R. 4-Hydroxy-2-nonenal adduction of extracellular signal-regulated kinase (Erk) and the inhibition of hepatocyte Erk-Est-like protein-1-activating protein-1 signal transduction. Mol Pharmacol 71 (2007) 871-883
7. Dominguez-Rodriguez A., Abreu-Gonzalez P., de la Rosa A., et al. Role of endogenous interleukin-10 production and lipid peroxidation in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty, interleukin-10 and primary angioplasty. Int J Cardiol 99 (2005) 77-81
8. Yun M.R., Im D.S., Lee S.J., et al. 4-Hydroxynonenal contributes to macrophage foam cell formation through increased expression of class A scavenger receptor at the level of translation. Free Radic Biol Med 45 (2008) 177-183
9. Johnson J.L. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 5 (2007) 265-282
10. Risinger Jr. G.M., Hunt T.S., Updike D.L., Bullen E.C., and Howard E.W. Matrix metalloproteinase-2 expression by vascular smooth muscle cells is mediated by both stimulatory and inhibitory signals in response to growth factors. J Biol Chem 281 (2006) 25915-25925
11. Hlawaty H., Jacob M.P., Louedec L., et al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler Thromb Vasc Biol 29 (2009) 518-524
12. Caird J., Napoli C., Taggart C., Farrell M., and Bouchier-Hayes D. Matrix metalloproteinases 2 and 9 in human atherosclerotic and non-atherosclerotic cerebral aneurysms. Eur J Neurol 13 (2006) 1098-1105
13. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85 (2005) 1-31
14. Mehrabian M., Allayee H., Wong J., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 91 (2002) 120-126
15. Jawien J., Gajda M., Rudling M., et al. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest 36 (2006) 141-146
16. Back M., Sultan A., Ovchinnikova O., and Hansson G.K. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 100 (2007) 946-949
17. Jawien J., Gajda M., Wolkow P., et al. The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 59 (2008) 633-639
18. Qiu H., Gabrielsen A., Agardh H.E., et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 103 (2006) 8161-8166
19. Zhou Y.J., Wang J.H., Li L., et al. Expanding expression of the 5-lipoxygenase/leukotriene B4 pathway in atherosclerotic lesions of diabetic patients promotes plaque instability. Biochem Biophys Res Commun 363 (2007) 30-36
20. Aiello R.J., Bourassa P.A., Lindsey S., et al. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 22 (2002) 443-449
21. Spanbroek R., Grabner R., Lotzer K., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 100 (2003) 1238-1243
22. De Caterina R., and Zampolli A. From asthma to atherosclerosis--5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med 350 (2004) 4-7
23. Jawien J. The putative role of leukotrienes in experimental atherogenesis. Pol Arch Med Wewn 119 (2009) 90-93
24. Funk C.D. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 4 (2005) 664-672
25. Back M., Bu D.X., Branstrom R., et al. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA 102 (2005) 17501-17506
26. Heller E.A., Liu E., Tager A.M., et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 112 (2005) 578-586
27. Subbarao K., Jala V.R., Mathis S., et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol 24 (2004) 369-375
28. Dwyer J.H., Allayee H., Dwyer K.M., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350 (2004) 29-37
29. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
30. Cipollone F., Mezzetti A., Fazia M.L., et al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol 25 (2005) 1665-1670
31. Radmark O., and Samuelsson B. 5-lipoxygenase: regulation and possible involvement in atherosclerosis. Prostaglandins Other Lipid Mediat 83 (2007) 162-174
32. Yun M.R., Im D.S., Lee S.J., et al. 4-Hydroxynonenal enhances CD36 expression on murine macrophages via p38 MAPK-mediated activation of 5-lipoxygenase. Free Radic Biol Med 46 (2009) 692-698
33. Lee S.J., Seo K.W., Yun M.R., et al. 4-Hydroxynonenal enhances MMP-2 production in vascular smooth muscle cells via mitochondrial ROS-mediated activation of the Akt/NF-kappaB signaling pathways. Free Radic Biol Med 45 (2008) 1487-1492
34. Luo M., Jones S.M., Peters-Golden M., and Brock T.G. Nuclear localization of 5-lipoxygenase as a determinant of leukotriene B4 synthetic capacity. Proc Natl Acad Sci USA 100 (2003) 12165-12170
35. Back M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther 23 (2009) 41-48 sponsored by the International Society of Cardiovascular Pharmacotherapy
36. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
37. Katsuda S., and Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb 10 (2003) 267-274
38. Pasterkamp G., Schoneveld A.H., Hijnen D.J., et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 150 (2000) 245-253
39. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
40. Zhao L., Moos M.P., Grabner R., et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 10 (2004) 966-973
41. Werz O., Klemm J., Samuelsson B., and Radmark O. 5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc Natl Acad Sci USA 97 (2000) 5261-5266